A study experimented VC in combination with each of eribulin mesylate, tamoxifen, fulvestrant, and trastuzumab on a variety of breast cancer cell lines (MCF7, SK-BR3, MDA-MB-231, and breast epithelial cells MCF10A), have shown that high-dose VC with each of those anti-cancer drugs had decreased the cell viability of cancer cells more comprehensively than high-dose of VC or chemotherapy alone (90)
doi: 10.1111/nyas.14041 9
What If Your Research Protocol Requires You to Stop One Compound but Continue the Other
The first oral GLP-1 pill for weight loss has been approved in the UK by the medicines regulator, meaning there is an opportunity to bring effective treatment to people who could not, or would not, use an injection
PlexusDx can support that conversation, not replace it
This is especially important during the higher dose phases